GLP-1s are reshaping healthcare: Wells Fargo
Robin Wenzel, head of Wells Fargo Industry Insights, explains how GLP-1 semaglutides are reshaping the healthcare business.
GLP-1 boom expands beyond weight loss
A panel examines the expansion of GLP-1 medications beyond weight loss, exploring new medical uses, potential side effects and what the next wave of these blockbuster drugs could mean for patients on 'Barron's Roundtable.'
DSA candidates are so radical they make Kamala Harris seem conservative: Jillian Michaels
'Keeping It Real' podcast host Jillian Michaels discusses the leftward shift in the Democratic Party and comments on a survey saying 10% of couple use GLP-1 drugs before wedding on 'Varney & Co.'
Tom Brady teams with digital health firm eMed to expand GLP-1 weight loss medication access
NFL legend Tom Brady is partnering with eMed to tackle the obesity epidemic by making GLP-1 weight loss medications accessible through employer health benefits.
Pfizer CEO on primary care, GLP-1 outlook and innovation timeline
Albert Bourla, Pfizer Chairman & CEO, discusses strong performance in primary care and the game-changing Metsera acquisition for GLP-1 set to launch by 2028 on 'Mornings with Maria.'
Tom Brady opens up about his health amid GLP-1 surge: Water, movement and discipline
Seven-time Super Bowl champ Tom Brady says he wants to break the stigma around willpower as he joins eMed's mission to bring GLP-1 weight-loss support to workers.
Novo CEO outlines long-term strategy amid Trump-era drug talks: ‘We’re here to stay’
Novo Nordisk President and CEO Mike Doustdar joins ‘Mornings with Maria’ to discuss the launch of the first GLP-1 weight-loss pill in the U.S., the lawsuit against Hims & Hers and talks with the Trump administration on drug pricing.
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
Telehealth company Hims & Hers cancels $49 monthly weight-loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.
Pfizer CEO addresses growing competition in weight-loss drugs
Pfizer CEO Albert Bourla discusses Pfizer’s Q4 adjusted earnings and the competitive landscape for weight-loss drugs on ‘The Claman Countdown.’
Restaurant owner reveals surprising impact of Ozempic on dining habits
Celebrity chef and restaurant owner Andrew Gruel joins ‘Varney & Co.’ to break down the surprising ways weight loss drugs are hitting restaurant menus, alcohol sales and profit margins across the country.
Novo Nordisk executive reports high interest for once-daily, oral weight-loss pill
Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss medication on FOX Business, saying there's "a lot of excitement."
Wegovy rolls out once-daily weight loss pill; Novo Nordisk exec says not ‘much difference’
Novo Nordisk executive vice president of U.S. operations Dave Moore discusses the drugmaker’s newly launched once-daily oral weight-loss pill on ‘The Claman Countdown.’
Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend
Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand for high-protein foods and fitness gear.
FDA Commissioner Dr. Marty Makary: We've never had this 'essential' conversation on health
FDA Commissioner Dr. Marty Makary addresses why obesity is on the decline and discusses the Trump administration's deal that slashes related drug costs on 'The Evening Edit.'
Jillian Michaels calls IOC’s potential ban on transgender athletes a ‘win for women’
Fitness guru Jillian Michaels joins ‘Varney & Co.’ to analyze a report that the International Olympic Committee is considering banning transgender athletes from women’s events.
Trump says Ozempic prices will be 'much lower' for Americans
President Donald Trump said there will Ozempic prices will be lower after negotiations with Novo Nordisk as part of his broader initiative to reduce prescription drug costs.
Costco members will soon have access to weight-loss shots at a major discount
Costco is partnering with the healthcare company Novo Nordisk to give members access to GLP-1 medications at just $499 for a four-week supply.
Wegovy pill hits 16% loss in trial, Novo says
Novo Nordisk President Dave Moore joins 'Mornings with Maria' to discuss the results of the Wegovy weight loss pill and President Donald Trump's efforts to make medicine more affordable.
Novo Nordisk CEO steps down as Wegovy maker faces increased competition
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.
Eli Lilly enters 'beginning of new era' with oral weight loss medicine
Eli Lilly & Company Chairman and CEO Dave Ricks on their 'breakthrough' in weight-loss drug research, a U.S. manufacturing focus and lowering prescription prices even amid tariffs.